This randomized controlled trial aims to evaluate the efficacy of preoperative vaginal cleansing with 5% povidone-iodine in reducing postoperative infectious morbidity among women undergoing cesarean section. The primary outcomes include wound-related complications, while secondary outcomes include postoperative fever, endometritis, wound infection, and white blood cell count.

开始日期2027-05-01

申办/合作机构

Al-Azhar University

NCT04200729

/ Not yet recruiting临床4期IIT

Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis

The purpose of this study is to determine the effect of intra-abdominal irrigation with povidone-iodine (PVI) versus usual care on the rate of 30-day postoperative intra-abdominal abscesses (IAA) and to determine the effect of PVI irrigation versus usual care on 30-day hospital length of stay(LOS) and 30-day readmissions.

开始日期2027-03-01

申办/合作机构

The University of Texas Health Science Center at Houston

CTRI/2026/09/117982

/ Not yet recruiting临床4期

A Prospective, Randomised, Single-Masked, Parallel-Group Controlled Trial Comparing Intravitreal 1 percent Povidone-Iodine versus Standard Intravitreal Antibiotic Therapy for Endophthalmitis post Cataract surgery - NIL

开始日期2026-10-20

申办/合作机构-

100 项与聚维酮碘相关的临床结果

登录后查看更多信息

100 项与聚维酮碘相关的转化医学

登录后查看更多信息

100 项与聚维酮碘相关的专利（医药）

登录后查看更多信息

4,193

项与聚维酮碘相关的文献（医药）

2026-12-01·JOURNAL OF EQUINE VETERINARY SCIENCE

In vitro biofilm-forming ability and antiseptic and antimicrobial susceptibility of bacterial strains derived from surgical-site infections in equine orthopedic surgery

Article

作者: Mita, H ; Kuroda, T ; Ohta, M ; Nomura, M

BACKGROUND:

Surgical site infection (SSI) is a serious complication of equine orthopedic surgery. Biofilm formation by the causative bacteria contributes to treatment failure by conferring tolerance to antimicrobial agents and disinfectants; however, data on biofilm formation and antiseptic or antimicrobial exposure in equine clinical isolates are limited.

AIMS/OBJECTIVES:

Our objectives were to evaluate the biofilm-forming ability of bacterial strains isolated from postoperative equine orthopedic SSI and to assess the susceptibility of established biofilms to disinfectants and antimicrobial agents after short-term exposure.

METHODS:

A total of 102 bacterial strains were evaluated. Biofilms were formed using a 96-well plate with a peg-lid system, and biofilm biomass was quantified spectrophotometrically. Biofilms were exposed for 10 min to five agents: povidone-iodine, chlorhexidine, benzalkonium chloride, gentamicin, and ampicillin. Viable bacteria were quantified by colony-forming unit counts, and effects were expressed as log reductions relative to controls.

RESULTS:

Biofilm-forming ability varied among bacterial groups, with Acinetobacter spp. showing the highest optical density (1.68 ± 0.91) and methicillin-sensitive Staphylococcus aureus exhibiting lower values (0.12 ± 0.08). Povidone-iodine achieved a > 5 log₁₀ CFU reduction across all bacterial groups. In Gram-negative bacteria, it achieved significantly greater reductions than chlorhexidine and benzalkonium chloride (1-3 log₁₀ CFU reduction). Antimicrobial agents showed little bactericidal activity against 24-h biofilms.

CONCLUSION:

Biofilm formation at surgical sites should be considered following equine orthopedic surgery. In this in vitro study, povidone-iodine had greater activity than other agents against established biofilms, suggesting its potential usefulness for biofilm-associated surgical site disinfection.

2026-10-01·INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Impact of ethyl alcohol nasal treatment on hospital-onset Staphylococcus aureus bacteremia at a tertiary health system

Article

作者: Roberts, Scott C. ; Sather, Jennifer H. ; Aniskiewicz, Michael ; Nucci, Donna

Abstract:

Introduction::

Staphylococcus aureus is a common pathogen that can cause nosocomial infection. Ethyl alcohol has emerged as a potential alternative to mupirocin and povidone-iodine for nasal decolonization; however, data on real-world application are limited.

Methods::

A quasi-experiment study was performed. Twice daily 62% ethyl alcohol nasal swabs were offered to inpatients at risk for MRSA acquisition. Compliance was monitored and reasons for non-adherence were evaluated. Rates of hospital-onset S. aureus bacteremia were compared pre and postintervention.

Results::

A total of 274,999 doses of ethyl alcohol were administered to 12,179 high-risk inpatients with a compliance rate of 82.7%. Reasons for non-compliance centered on product characteristics, patient comorbidities, and perceived lack of benefit from patients and healthcare personnel. There were fewer overall hospital-onset S. aureus bacteremia events (1.97 events/10,000 patients days predecolonization compared to 1.49 events/10,000 patient days with decolonization, P = .013). This difference was primarily driven by reduced MRSA bacteremia events (0.61 events/10,000 patient days predecolonization versus 0.36 with decolonization, P = .009) rather than MSSA bacteremia events (1.31 events/10,000 patient days predecolonization versus 1.13 events/10,000 patient days with decolonization, P = .232). On a per-patient basis during the intervention period, there were fewer MRSA bacteremia events in patients receiving decolonization (6.57 events per 10,000 patients) compared to high-risk, but eligible, patients who did not receive decolonization (19.62 episodes per 10,000 patients, P = .044).

Conclusion::

Twice daily ethyl alcohol nasal treatment may be a viable alternative to existing S. aureus nasal decolonization options.

2026-10-01·JOURNAL OF ARTHROPLASTY

The One-Year Infection Rates After Vancomycin Powder and Dilute Povidone-Iodine Lavage in High-Risk Primary Total Joint Arthroplasty: A Multicenter Randomized Controlled Trial

Article

作者: Liimakka, Adriana ; Tang, Alex ; Baskar, Suriya ; Hong, Ian ; Christensen, Tommy ; Lombardi, Paul ; Rozell, Joshua C. ; Higuera, Carlos A. ; Vyge, Olivia ; Huffman, Nick ; Malik, Martin ; Meftah, Morteza ; Andriani, Nicholas ; DeBenedetti, Anne ; Fermin, Lenin ; Johnson, Rose ; Schwarzkopf, Ran ; Davis, Joshua ; Dennis, Douglas A. ; Long, William J. ; Oliver, Dylan ; Villa, Jesus M. ; Levine, Brett R. ; Raymond, Hayley ; Chen, Antonia F. ; Piuzzi, Nicolas S. ; Rajahraman, Vinaya ; Schaffer, Olivia ; Weinblatt, Aaron ; Poletick, Eileen ; Mendez, Judith ; Aggarwal, Vinay K. ; Dundon, John ; Klika, Alison ; Pasqualini, Ignacio ; Kissin, Yair D. ; Saba, Braden V. ; Rossman, Stephen ; Wittig, James ; Cooper, H. John ; Seref-Ferlengez, Zeynep ; Waren, Daniel ; Fowler, Mia J. ; Macaulay, William ; Yoon, Richard

BACKGROUND:

Given the severe morbidity, mortality, and substantial cost of periprosthetic joint infection (PJI), substantial research has been conducted to compare perioperative and postoperative infection-prevention strategies. To our knowledge, there are no studies to date that have evaluated the 1-year efficacy of intraoperative vancomycin powder and/or dilute povidone-iodine lavage versus saline lavage in total joint arthroplasty. We previously reported no significant group differences at 3 months in a large multicenter randomized controlled trial. The present study reports 1-year outcomes of the same cohort.

METHODS:

In this prospective, multicenter trial, 2,053 high-risk patients undergoing primary, unilateral total hip arthroplasty (THA) or total knee arthroplasty (TKA) were randomized to one of four intraoperative protocols: vancomycin powder, dilute povidone-iodine, vancomycin povidone-iodine protocol (VPIP, combination), or saline lavage control. The primary outcome was 1-year PJI resulting in septic revision surgery. Analyses were conducted on a per-protocol basis using Chi-square tests stratified by procedure. At 1 year, complete follow-up was available for 798 THA and 1,032 TKA patients after accounting for withdrawals, loss to follow-up, and nine unrelated deaths.

RESULTS:

In the THA cohort, PJI occurred in 0.5% of vancomycin patients, 1.7% of iodine patients, 1.9% of VPIP patients, and 1.1% of saline patients (P = 0.62). In the TKA cohort, PJI occurred in 1.6% of vancomycin patients, none of the iodine patients, 2.0% of VPIP patients, and 0.4% of saline patients (P = 0.05). There were no significant differences between study groups at 0 to 3 months (P = 0.14 for THA, P = 0.13 for TKA), 3 to 12 months (P = 0.67 for THA, P = 0.80 for TKA), or combined 0 to 12 months (P = 0.62 for THA, P = 0.05 for TKA).

CONCLUSIONS:

There were no significant differences in 1-year PJI rates observed across prophylactic strategies in high-risk primary THA or TKA. These findings suggest that intraoperative antiseptic and antibiotic protocols may have limited influence on longer-term outcomes.

项与聚维酮碘相关的新闻（医药）

2026-10-12

·BioSpace

Study Shows I2Pure’s Molecular Iodine Formulations Rapidly Kill Multidrug-Resistant Pathogens without Residual Staining

Novel, proprietary formulations show broad-spectrum activity against drug-resistant bacteria and emerging fungal pathogens and remain effective for 24 hours after drying. ASHBURN, Va.--(BUSINESS WIRE)--I2Pure today announced the publication of an independent study conducted by researchers at the University of California San Diego demonstrating the rapid, broad-spectrum antimicrobial activity of several of the company’s proprietary molecular iodine formulations against clinically important bacterial and fungal pathogens. The study evaluated three topical formulations, including aqueous and non-aqueous liquids and a topical gel. The study was led by UC San Diego scientist Elisabet Bjånes, PhD, and published in Antimicrobial Agents and Chemotherapy , a journal of the American Society for Microbiology (ASM), under the title, "Rapid broad-spectrum activity of molecular iodine against multidrug-resistant bacterial and fungal pathogens without residual staining." The study also included contributions from I2Pure Chief Scientist Ilker Bayer, PhD, and I2Pure Chief Medical Officer Victor Nizet, MD. View pro about them ( ) here. Key findings The research team evaluated three I2Pure molecular iodine (I₂) formulations against 17 clinically relevant bacterial and fungal pathogens, including multidrug-resistant organisms and emerging nosocomial threats. Among the findings: All three formulations achieved rapid, broad-spectrum antimicrobial activity, commonly producing 3–4 log10 reductions in colony-forming units (CFUs) — greater than 99.9% killing —within just 15 seconds of contact. Potent activity was observed against major healthcare-associated pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), Klebsiella pneumoniae , and Pseudomonas aeruginosa , as well as fungal pathogens including Candida albicans and the emerging, difficult-to-treat Candidozyma auris . Compared with standard povidone-iodine (PVP-I), I2Pure's formulations exhibited minimal residual staining and were readily removed from hospital textiles after a brief water rinse — addressing a longstanding practical limitation of traditional iodine antiseptics in hospital settings. All three formulations retained substantial antimicrobial activity after drying on surfaces for 24 hours, supporting potential application in environmental decontamination as well as topical antisepsis. "We were excited to see these strong results from an independent academic study," commented I2Pure’s Chief Scientist, Dr. Ilker Bayer. “Our goal has been to harness the potent antimicrobial properties of molecular iodine while overcoming practical limitations associated with traditional iodine formulations. Seeing our proprietary formulations independently evaluated against such a broad range of important pathogens provides valuable validation of our approach.” “This study reinforces our internal research and other assessments of I2Pure’s technology and energizes us to bring more products to market,” said Jeff Jochims, I2Pure CEO. “We’re proud to be developing and commercializing products designed to be highly effective, persistent, and more environmentally friendly than traditional options.” About I2Pure I2Pure is an iodine technology company dedicated to advancing health and biosafety through its patented, non-toxic molecular iodine solutions. I2Pure's mission is to prevent pathogenic threats to the world. Its proprietary technology platform has potential applications across healthcare, industrial biosafety, consumer products, and food processing and can be delivered directly or through carriers in solutions, nanoparticles, polymers, and coatings. View the I2Pure website for more information or contact the company at info@i2pure.com . Contacts info@i2pure.com

临床结果微生物疗法

2026-09-24

·医药云端工作室

预填报！粤滇牵头省际联盟集采，68个品种、274个品规（附名单）

编辑：子非鱼 9月24日，广州GPO发出《关于广东云南省际联盟集中带量采购相关药品信息预填报工作的公告》，公告显示，按照国家医保局工作部署，广东、云南两省拟分别牵头开展部分化学药品省际联盟集中带量采购，现开展相关药品信息预填报工作，预填报时间：9月28日09:00-10月15日18:00。本次共梳理形成68个化学药通用名、合计274个申报品规的预填报清单，其中广东牵头35个品种（136个品规）、云南牵头33个品种（138个品规），标志着本轮联盟集采正式进入企业信息归集与需求摸排阶段。填报资质与材料要求全面收紧公告明确，本次信息填报覆盖四类主体：参比制剂、过评仿制药（含视同过评）、未过评仿制药（含未开放一致性评价通道品种），即所有合规上市品种均可参与，不存在过评门槛限制。但企业需提交的证明材料较以往更为细化。除基础企业、药品注册信息外，必须上传GMP符合性检查证明（进口药需公证翻译）、近5年内跨24个月以上的上市销售放行记录、关联股权关系证明、知识产权无侵权承诺、年度产能声明等全套材料。其中知识产权条款惩戒力度明确：申报截止前未提交无侵权承诺的产品，已挂网的将予以撤网、未挂网的协议期内不再受理挂网申请。品种结构长尾特征显著，特殊品类集中入围从清单结构看，本轮集采明显跳出过往国采聚焦大口服、大注射剂的传统范围，呈现“长尾专科药+外用/特殊剂型为主”的特征： 1、外用制剂占比突出。他克莫司、吡美莫司、莫匹罗星、夫西地酸、卡泊三醇等皮肤科软膏剂合计超40个品规，氯己定、聚维酮碘、依沙吖啶、炉甘石等外用消毒/护理液体剂超60个品规，是本轮清单中剂型占比最高的板块。 2、儿童与口服液体剂扩容明显。氨酚麻美、左西替利嗪、丙卡特罗、西甲硅油、二甲硅油、小儿氨酚黄那敏颗粒等儿科常用液体制剂合计超40个品规，基层门诊、儿科用药成为本轮集采重点摸排方向。 3、高值与特殊属性品种纳入值得关注。碘[125I]密封籽源（放射性医用药品）、肝素封管注射液、两性霉素B脂质体注射剂、白消安注射剂、阿昔替尼口服常释剂型、泊沙康唑口服液体剂等重症、罕见病、肿瘤靶向、特殊诊疗用药均在清单内，其中放射性籽源、院内封管液这类长期未进入集采视野的院内配套制剂首次纳入省际联盟采购范围。行业影响本次预填报是后续医疗机构报量、正式竞价的前置环节，企业填报的品规范围将直接进入医院需求选择池，漏报、错报会直接影响后续中选资格与平台挂网权限。从品种选择趋势看，继生物药、中成药之后，化药集采的下沉方向已明确转向院外常用、小众专科、外用与儿童制剂这类“长尾市场”，过往这类品种因单品市场规模有限、企业数量分散长期未被集采覆盖，未来将逐步成为地方联盟集采的常态化挖掘对象。对企业而言，需提前梳理GMP、产能、历史销售等佐证材料，重视知识产权合规，避免因信息不全错失参与资格。最终正式采购范围、竞价规则仍以后续发布的正式采购公告为准。声明：本公众号内容旨在为医药行业人士提供行业动态，并不构成任何就医/用药/购药/投资建议，内容也不保证完整性和准确性，你看到此内容并不意味着你是本公众号的特定读者，请谨慎阅读。关注公众号，获取可靠、专业的资讯和分析内容

2026-07-20

·BioSpace

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO ® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ ® (ranibizumab-nuna) i , an FDA-approved biosimilar referencing LUCENTIS ii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow's retina portfolio and reinforce Harrow’s commitment to generating quality evidence that strengthens physician confidence, improves patient experience, and supports long-term product adoption and innovation. “ASRS is one of the premier scientific meetings in retina, and we're excited to share data that continues to strengthen the foundation supporting our growing retina franchise,” said Mark L. Baum, Chief Executive Officer of Harrow. “We believe durable commercial success is built on strong clinical evidence, generated before FDA-approval, and then robust supportive data sets subsequently produced. These studies further expand the evidence supporting IHEEZO while adding to the growing body of real-world experience for BYOOVIZ, reflecting our long-term commitment to retina specialists and the patients they treat.” One presentation highlighted interim findings from an investigator-initiated, prospective, randomized study of 150 patients comparing IHEEZO versus subconjunctival lidocaine. While these preliminary data represent an early look at the data, investigators observed encouraging trends toward less post-procedure pain, a better post-injection patient experience, and fewer ocular symptoms through 24 hours following intravitreal injection among patients treated with IHEEZO. Harrow believes these early findings provide an encouraging signal supporting further investigation in a larger patient population. Importantly, Harrow continues to enroll QUELL, a prospective, randomized, multi-center clinical trial of approximately 236 subjects that is being conducted under an active Investigational New Drug (IND) application. QUELL is designed to generate robust clinical evidence evaluating post-injection pain, patient experience, procedural performance, and safety in a substantially larger patient population, with topline data expected in the fourth quarter of 2026. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Another real-world study retrospectively evaluated whether IHEEZO's proprietary low-viscosity gel formulation interferes with antisepsis when used with chlorhexidine before intravitreal injection. Across nearly 20,000 injections, investigators observed no evidence of an increased endophthalmitis risk compared with a legacy tetracaine/povidone-iodine preparation. Although retrospective and not intended to demonstrate statistical superiority, the findings provide further confidence that physicians can realize the patient-experience benefits of IHEEZO's low-viscosity gel formulation without introducing additional procedural risk associated with antisepsis. “These studies help build the scientific foundation supporting IHEEZO,” said Amir Shojaei, Chief Scientific Officer of Harrow. “The early interim randomized data suggest the potential to improve the patient experience, while the large real-world analysis provides reassuring evidence regarding procedural safety. We look forward to completing enrollment in QUELL, which we believe will provide the most comprehensive evaluation of IHEEZO in retina to date.” Finally, Samsung Bioepis presented interim findings from a large-scale, real-world post-marketing surveillance study of BYOOVIZ. Full results from this study are being announced jointly with Samsung Bioepis today. “Between the continued expansion of the clinical evidence supporting IHEEZO, the recent launch of BYOOVIZ, and the ongoing growth of our retina franchise, we believe Harrow is increasingly well-positioned as a trusted long-term partner to retina specialists,” Baum concluded. “We appreciated the opportunity to engage with physicians throughout ASRS and look forward to sharing additional updates later this year.” IHEEZO ® (chloroprocaine hydrochloride ophthalmic gel) 3%, for topical ophthalmic use INDICATIONS AND USAGE IHEEZO is an ester anesthetic indicated for ocular surface anesthesia. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation WARNINGS AND PRECATIONS Not for Injection or Intraocular Administration. Corneal Injury Due to Insensitivity. Corneal Opacification For Administration by Healthcare Provider: IHEEZO is not intended for patient self-administration ADVERSE REACTIONS Most common adverse reaction is mydriasis (approximately 25%) Please see full Prescribing information BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use is a biosimilar to LUCENTIS (ranibizumab injection) INDICATIONS AND USAGE BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Myopic Choroidal Neovascularization (mCNV) IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Ocular or periocular infections Hypersensitivity WARNINGS AND PRECAUTIONS Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection Increases in intraocular pressure (IOP) have been noted both pre- and post intravitreal injection There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors ADVERSE REACTIONS The most common adverse reactions (reported more frequently in ranibizumab treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP Please see full Prescribing Information About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn . About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit and follow us on LinkedIn and X . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Contacts: Mike Biega Vice President of Investor Relations and Communications mbiega@harrowinc.com 617-913-8890 i Byooviz is a trademark of Samsung Bioepis Co., Ltd. ii Lucentis is a trademark of Genentech, Inc.

临床结果

100 项与聚维酮碘相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00863	聚维酮碘	D08AG02 G01AX11 D09AA09	DB06812

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
咽炎	澳大利亚	Noumed Pharmaceuticals Pty Ltd.	2026-09-30
刺戳创伤	澳大利亚	Noumed Pharmaceuticals Pty Ltd.	2026-09-29
传染性皮肤病	澳大利亚	Noumed Pharmaceuticals Pty Ltd.	2026-09-29
褥疮	日本	Nikko Sangyo Co., Ltd.	1999-07-01
细菌感染和真菌病	澳大利亚	Orion Laboratories Pty Ltd.	1991-09-07
烧伤感染	澳大利亚	Orion Laboratories Pty Ltd.	1991-09-07
慢性咽炎	澳大利亚	Orion Laboratories Pty Ltd.	1991-09-07
眼部疾病	美国	Alcon Pharmaceuticals Ltd.	1986-12-17
皮肤溃疡	韩国	SAMIL PHARMACEUTICAL Co., Ltd.	1976-07-10
烧伤	韩国	SAMIL PHARMACEUTICAL Co., Ltd.	1976-07-10
消毒剂	日本	-	1965-11-01
外阴阴道念珠菌病	中国	亚宝药业四川制药有限公司	-
痔疮	中国	亚宝药业四川制药有限公司	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
牙菌斑	临床3期	美国	Colgate-Palmolive Co.	2007-10-01
真菌性角膜炎	临床2期	-	iVIEW Therapeutics, Inc.	2026-08-01
腺病毒性结膜炎	临床2期	印度	iVIEW Therapeutics, Inc.	2023-02-20
腺病毒科感染	临床2期	印度	iVIEW Therapeutics, Inc.	2023-02-20
急性细菌性结膜炎	临床2期	中国	iVIEW Therapeutics, Inc.	2023-01-05
急性细菌性结膜炎	临床2期	中国	Bio-Concept Laboratories, Inc.	2023-01-05
急性腺病毒滤泡性结膜炎	临床2期	中国	Bio-Concept Laboratories, Inc.	2022-01-04
急性腺病毒滤泡性结膜炎	临床2期	中国	iVIEW Therapeutics, Inc.	2022-01-04
结膜炎	临床2期	美国	Protheragen, Inc.	-
新型冠状病毒感染	临床前	美国	iVIEW Therapeutics, Inc.	2020-09-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2026	N/A	眼内炎	7	Intravitreal Povidone-Iodine 1.25% (acute exogenous endophthalmitis + severe antibiotic allergies)	觸願觸醖獵積醖觸鹽糧(廠廠鹽鏇製積獵範繭憲) = 餘壓願鹹願範鏇製範製鏇鑰壓淵願鹽獵鹹遞鹽 (願網鑰選製範積憲鹽顧, 0.99) 更多	积极	2026-05-03
NCT04075526 (CTgov)	临床1期	骨关节炎 \| 感染	2,129	Povidone iodine+Vancomycin powder (Povidone Iodine and Vancomycin Powder)	遞願獵醖糧構鏇獵簾鹽 = 製觸簾夢襯築積積鹹艱糧廠遞網鹽遞艱製鏇選 (積窪積選簾齋艱醖鏇鹹, 窪築襯構鏇築醖簾網鑰 ~ 淵選願製觸淵構衊壓製) 更多	-	2026-02-17
				Povidone iodine (Povidone Iodine Alone)	遞願獵醖糧構鏇獵簾鹽 = 範鬱簾簾襯製餘觸選製糧廠遞網鹽遞艱製鏇選 (積窪積選簾齋艱醖鏇鹹, 醖醖壓鹽齋獵壓鹽鏇鬱 ~ 顧鏇衊夢壓艱繭醖齋鹹) 更多
NCT04210505 (Pubmed \| Infect Control Hosp Epidemiol)	临床4期	感染	469	Intranasal povidone-iodine (PVI)	願積艱願蓋蓋醖構窪繭(鹹夢鹹遞廠遞窪鹹夢糧) = 獵選製鏇憲鹽壓餘鏇獵壓鬱鬱積糧範鏇糧憲觸 (構糧構衊醖觸廠淵蓋願 )	积极	2026-02-04
NCT01841242 (CHLOVIS, Pubmed \| J Am Coll Cardiol)	临床4期	感染	2,272	2% alcohol-based chlorhexidine	製憲壓淵窪範糧窪鬱襯(艱範獵鬱餘獵繭構壓鑰) = 鬱觸顧鬱壓餘構廠壓憲構壓鑰鏇襯餘鹽顧製艱 (窪廠鹹廠窪壓憲壓獵積 ) 更多	不佳	2026-01-01
				4-phase povidone-iodine-alcohol skin preparation	製憲壓淵窪範糧窪鬱襯(艱範獵鬱餘獵繭構壓鑰) = 製膚膚衊鹽獵鹽夢鏇襯構壓鑰鏇襯餘鹽顧製艱 (窪廠鹹廠窪壓憲壓獵積 ) 更多
NCT05816070 (CTgov)	临床2期	急性细菌性结膜炎	129	IVIEW-1201 (IVIEW-1201)	簾選夢簾膚簾餘築餘製: P-Value = 0.0137	-	2025-06-15
				Ofloxacin Eye Drops (Ofloxacin Eye Drops)
NCT03560193 (CLEAN 2, Pubmed \| Intensive Care Med)	临床4期	手术伤口感染	3,242	2% chlorhexidine-alcohol	醖鹹淵選糧築艱觸簾窪(範憲膚餘憲淵願襯範廠) = 範積鏇簾願鬱顧壓鬱鑰淵蓋鏇簾壓繭醖廠範鹽 (廠膚觸獵餘廠願構鏇網 ) 更多	不佳	2024-12-01
				5% povidone-iodine-alcohol	醖鹹淵選糧築艱觸簾窪(範憲膚餘憲淵願襯範廠) = 遞願製鏇齋鹽糧網獵膚淵蓋鏇簾壓繭醖廠範鹽 (廠膚觸獵餘廠願構鏇網 ) 更多
NCT05529173 (CTgov)	临床4期	手术伤口感染 \| 耐甲氧西林金黄色葡萄球菌感染	192	Povidone-Iodine 10% (Treatment)	繭窪憲願選築積壓繭鑰(蓋範鏇製齋獵簾廠選糧) = 網獵鑰鏇糧鑰餘鬱窪鹹觸鹽鹽壓廠窪鹽壓夢糧 (醖顧觸願繭觸製網選願, 鑰繭糧繭簾蓋鹽鏇鏇淵 ~ 獵餘鏇夢鏇蓋壓網鑰襯) 更多	-	2024-11-13
				0.9% NaCl Solution (Placebo)	繭窪憲願選築積壓繭鑰(蓋範鏇製齋獵簾廠選糧) = 範齋積鏇蓋鏇壓顧網鹹觸鹽鹽壓廠窪鹽壓夢糧 (醖顧觸願繭觸製網選願, 廠鑰鏇鑰襯鏇廠餘襯網 ~ 窪製顧餘顧遞網構鬱齋) 更多
ERS2024	N/A	脑疾病 \| 恶性胸腔积液	190	Povidone Iodine + Talc	膚襯夢膚餘窪願醖膚餘(築鹹願膚築簾糧鹹範鏇) = There were no significant complications such as ARDS in any patient 艱壓鬱憲鹽構顧壓觸糧 (壓壓鏇淵鏇網構顧製廠 ) 更多	积极	2024-09-07
				Povidone Iodine + Talc (Pleurodesis during pleuroscopy)
NCT05816070 (ARVO2024)	临床2期	细菌性结膜炎	129	聚维酮碘滴眼液	遞顧窪築鬱鹽淵繭夢鏇(窪衊鹹構積築構構範鑰) = 蓋遞蓋淵鏇餘衊夢積蓋襯鏇築餘膚衊壓夢觸構 (觸憲積網糧壓鬱膚蓋壓 )	相似	2024-05-07
				氧氟沙星	遞顧窪築鬱鹽淵繭夢鏇(窪衊鹹構積築構構範鑰) = 獵餘壓衊壓糧鹽製鏇觸襯鏇築餘膚衊壓夢觸構 (觸憲積網糧壓鬱膚蓋壓 )
AUA2024	N/A	脓毒症	-	Rectal betadine preparation	觸選願鬱窪鹹淵遞憲鬱(窪膚鹹製網獵齋糧構窪) = 積製願遞襯衊齋鏇憲齋壓艱淵積襯壓窪鬱遞鑰 (繭鹽遞觸獵餘醖蓋廠膚 ) 更多	-	2024-05-01